^
    Back
    Association details:
    Biomarker:TP53 mutation
    Cancer:Lymphoma
    Drug Class:CD19-targeted CAR-T immunotherapy +
    CD22-targeted CAR-T immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ASH 2020
    Title:

    Anti CD19/22 Cocktail CAR T-Cell Therapy Can Improve the Outcomes of Patients with TP53-Mutated Relapsed/Refractory B-Cell Lymphoma

    Published date:
    11/04/2020
    Excerpt:
    CAR19/22 T-cell cocktail therapy can improve the outcome of r/r B-cell lymphoma with high-risk of functional classification of Tp53 mutation. The patients who achieved overall response at month three can greatly benefit from CAR19/22 T cell cocktail therapy with long-term favorable outcome.